FDA abortion pill review to continue into next year
Agency provides court-ordered update on safety study of mifepristone
AI-assisted coverage comparison, editor-supervised · How this was made

FDA abortion pill review to continue into next year
Photograph: abc News (embedded from source)
What this story says
- The Food and Drug Administration's safety review of the abortion pill mifepristone will continue into next year.
- The FDA provided a court-ordered update on its progress in a legal filing on Wednesday.
- The agency expects to finish a safety study by mid-December and issue a report on findings no later than March 2027.
- Abortion opponents have criticised the timeline, while the FDA was directed to provide the update by a federal appeals court.
Who covered it
Percentages are shares of the 95 outlets carrying a published leaning rating. 12 of the 107 outlets we know ran this story carry no rating and are not counted in them. Coverage measured .
Trust
42/100
Craft
59/100
Hype
41/100
107 sources · methodology
Missing from the right
Only 18 of the 95 outlets with a published leaning rating that ran this story are rated right.
A reader who follows the right would not have seen this. We report the absence rather than explain it: outlets choose what to cover for many reasons, and we have no evidence about which one applies here.
The Food and Drug Administration (FDA) has stated that its safety review of mifepristone, the nation's primary abortion pill, will continue into next year. This timeline was communicated in a legal filing submitted late Wednesday, fulfilling a court order. The agency anticipates completing a safety study of the drug by mid-December of this year. A report detailing the findings is expected to be released no later than March 2027, after which the FDA will determine whether to implement any new restrictions or modifications to the drug's use.
The FDA was directed to provide this update by a federal appeals court in New Orleans. This directive stems from a legal case brought by the state of Louisiana, which alleges that the mail delivery of mifepristone conflicts with the state's abortion ban. Mifepristone was first approved by the FDA in 2000 and has had its restrictions eased over time, including the removal of a requirement for in-person dispensing.
Disagreement on timeline for report
While ABC News, The Independent, and The Independent (US) report that a report on the findings is expected no later than March 2027, The Hill states the FDA revealed it won't publish its mifepristone safety review until March 2027. NBC News and NBC Dallas-Fort Worth report the FDA says it will complete the safety review in March, with NBC Dallas-Fort Worth specifying the review will be completed in March.
What the coverage left out
None of the left-rated digests mention the specific criticism from Gavin Oxley of Americans United for Life that the administration is 'clearly uninterested in mitigating the ongoing harms caused by the abortion pill'. The right-rated digest does not mention the FDA's expected completion date for the safety study (mid-December this year) or the expected date for the report on findings (no later than March 2027).
Coverage settled. We checked this 23 times and stopped on 13 Oct 2026, 20:15. The figures above are what it finished at.
How each side covered it
Our own reading of the reporting listed below, written from the outlets’ articles rather than quoted from them. The reasoning is set out on our methodology page.
Left
38 rated outlets
- Fifteen left-rated reports noted that the FDA's safety review of the abortion pill mifepristone will continue into next year. These reports stated that the FDA provided a court-ordered update on its progress in a legal filing late Wednesday. They also included that the agency expects to complete a safety study by mid-December this year and that a report on the findings is expected no later than March 2027. Several of these reports mentioned that the FDA was directed to provide the update by a federal appeals court in New Orleans, overseeing a case brought by the state of Louisiana. ABC News, the only full report in this category, also included criticism from Gavin Oxley of Americans United for Life, who called the move a lack of 'true leadership' and stated the administration was 'on the wrong side of women's health'.
Centre
39 rated outlets
- Six centre-rated reports highlighted that the FDA's safety review of the abortion pill mifepristone will continue into next year. These reports noted the FDA provided a court-ordered update on its progress in a legal filing late Wednesday. They also mentioned the agency expects to complete a safety study by mid-December this year and that a report on the findings is expected no later than March 2027. The Hill, a centre-rated outlet, reported that the FDA revealed it won't publish its mifepristone safety review until March 2027, sparking criticism from both sides.
Right
18 rated outlets
- Right-rated outlets reported that the Food and Drug Administration expects its safety review of the abortion pill mifepristone to continue into next year. Several indicated the review would conclude in March 2027, with some noting this was a delay from previous timelines.
- The digests mentioned the FDA provided an update in a court filing. Some reports highlighted that abortion opponents were unhappy with the extended timeline, with one mentioning pro-life groups blasting the FDA.
- The digests did not mention the specific cost estimate for the review. One report stated the FDA is conducting a study comparing outcomes for women using the pill versus those undergoing surgical abortions.
Questions about this coverage
- How did the left and right cover FDA abortion pill review to continue into next year?
- Of the 95 outlets on this story carrying a published leaning rating, 40% are rated left, 41% are rated centre, 19% are rated right. Those percentages are shares of the rated outlets, not of every outlet that ran it, which was 107. The sections above set out what each side emphasised, in its own terms.
- Is FDA abortion pill review to continue into next year left or right?
- Neither side dominates it. Of the 95 rated outlets on this story, 40% are rated left, 41% are rated centre, 19% are rated right, and no side holds the 70% this site would want before calling a field one-sided. A story is not left or right in any case; the outlets that carried it are what carry ratings.
- Is the coverage of FDA abortion pill review to continue into next year biased?
- FDA abortion pill review to continue into next year is one event reported by 107 outlets, and this page does not rate the story as biased or unbiased. What it publishes is the spread: which outlets ran it, where named rating organisations place each of them on the spectrum, and what each side chose to lead with. A leaning rating describes an outlet's record over time, not this article, and the two should not be run together.
- Which side is not reporting FDA abortion pill review to continue into next year?
- When we first saw this story, outlets rated right had barely covered it. Coverage accretes for hours after an event, so that is where to look rather than a verdict — the split above is the current count, and it is the one to read.
- Which outlets covered FDA abortion pill review to continue into next year?
- 107 that we know of, every one of them listed further up this page with a link to its own report and to what we hold on the publisher. Nothing here is a summary of somebody else's summary: the outlets are named so the original reporting can be read.
- When will the FDA complete its safety review of the abortion pill?
- The Food and Drug Administration expects to complete a safety study of the abortion pill mifepristone by mid-December this year. A report on the findings is anticipated no later than March 2027, after which the agency will decide on potential new restrictions or changes to the drug's use.
- Why did the FDA provide an update on the abortion pill review?
- The FDA provided the update in a legal filing late Wednesday because it was ordered to do so by a federal appeals court in New Orleans. This directive is part of a lawsuit brought by the state of Louisiana, which is challenging the mail delivery of mifepristone.
- What is the timeline for the FDA's report on the mifepristone safety review?
- The FDA expects to complete its safety study of mifepristone by mid-December this year. A report detailing the findings from this study is expected to be published no later than March 2027.
Read it at the source
107 outlets, grouped by the leaning a published rating gives them. Every headline links to the original; an underlined outlet name opens our profile of that publisher.
Left
38- Review could lead to changes (opens Dothan Eagle in a new tab)
Dothan Eagle — is Dothan Eagle biased? Our profile of this outlet
- Review could lead to changes (opens Record and Landmark in a new tab)
Record and Landmark — is Record and Landmark biased? Our profile of this outlet
- Feds unlikely to change abortion pill policy before next year (opens Ohio Capital Journal in a new tab)
Ohio Capital Journal — is Ohio Capital Journal biased? Our profile of this outlet
- Feds unlikely to change abortion pill policy before next year (opens alabamareflector.com in a new tab)
alabamareflector.com — is alabamareflector.com biased? Our profile of this outlet
- Feds unlikely to change abortion pill policy before '27 (opens Arizona Daily Sun in a new tab)
Arizona Daily Sun — is Arizona Daily Sun biased? Our profile of this outlet
- Feds unlikely to change abortion pill policy before next year (opens Kansas Reflector in a new tab)
Kansas Reflector — is Kansas Reflector biased? Our profile of this outlet
- Trump admin reveals post-midterm ‘crackdown’ plans in new court filing: report (opens Raw Story in a new tab)
- Feds unlikely to change abortion pill policy before next year (opens Wisconsin Examiner in a new tab)
Wisconsin Examiner — is Wisconsin Examiner biased? Our profile of this outlet
Show 30 more
- FDA says its safety review of abortion pill will continue into next year (opens RocketNews in a new tab)
RocketNews — is RocketNews biased? Our profile of this outlet
- Trump Admin Gears Up for Post-Midterm Crackdown on Abortion Drug (opens Talking Points Memo in a new tab)
Talking Points Memo — is Talking Points Memo biased? Our profile of this outlet
- FDA says its abortion pill review will finish in December, and it's report will be due by March (opens Arizona Mirror in a new tab)
Arizona Mirror — is Arizona Mirror biased? Our profile of this outlet
- FDA Says Safety Review Of Abortion Pill Will Continue Into Next Year (opens HuffPost in a new tab)
- Feds unlikely to change abortion pill policy before next year (opens Michigan Advance in a new tab)
Michigan Advance — is Michigan Advance biased? Our profile of this outlet
- FDA provides update on abortion pill review for Louisiana telehealth case (opens Louisiana Illuminator in a new tab)
Louisiana Illuminator — is Louisiana Illuminator biased? Our profile of this outlet
- Feds unlikely to change abortion pill policy before next year (opens South Dakota Searchlight in a new tab)
South Dakota Searchlight — is South Dakota Searchlight biased? Our profile of this outlet
- Feds unlikely to change abortion pill policy before next year (opens arkansasadvocate.com in a new tab)
arkansasadvocate.com — is arkansasadvocate.com biased? Our profile of this outlet
- Feds unlikely to change abortion pill policy before next year • Maine Morning Star (opens mainemorningstar.com in a new tab)
mainemorningstar.com — is mainemorningstar.com biased? Our profile of this outlet
- Feds unlikely to change abortion pill policy before next year (opens Stateline in a new tab)
- FDA Says Its Safety Review of Abortion Pill Will Continue Into Next Year (opens washingtonsun.com in a new tab)
washingtonsun.com — is washingtonsun.com biased? Our profile of this outlet
- FDA says its safety review of abortion pill will continue into next year (opens Sentinel Colorado in a new tab)
Sentinel Colorado — is Sentinel Colorado biased? Our profile of this outlet
- FDA says its safety review of abortion pill will continue into next year (opens Bowen Island Undercurrent in a new tab)
Bowen Island Undercurrent — is Bowen Island Undercurrent biased? Our profile of this outlet
- FDA says its safety review of abortion pill will continue into next year (opens Rocky Mountain Outlook in a new tab)
Rocky Mountain Outlook — is Rocky Mountain Outlook biased? Our profile of this outlet
- FDA says its review of abortion pill will continue into next year (opens thealbertan.com in a new tab)
thealbertan.com — is thealbertan.com biased? Our profile of this outlet
- FDA says its safety review of abortion pill will continue into next year (opens The Toronto Star in a new tab)
The Toronto Star — is The Toronto Star biased? Our profile of this outlet
- FDA says its review of abortion pill will continue into next year (opens El Paso Inc. in a new tab)
El Paso Inc. — is El Paso Inc. biased? Our profile of this outlet
- FDA says its safety review of abortion pill will continue into next year (opens The Seattle Times in a new tab)
The Seattle Times — is The Seattle Times biased? Our profile of this outlet
- FDA says its safety review of abortion pill will continue into next year (opens Associated Press News in a new tab)
Associated Press News — is Associated Press News biased? Our profile of this outlet
- FDA says its review of abortion pill will continue into next year (opens The Independent (US) in a new tab)
The Independent (US) — is The Independent (US) biased? Our profile of this outlet
- FDA says its review of abortion pill will continue into next year (opens The Independent in a new tab)
The Independent — is The Independent biased? Our profile of this outlet
- FDA says its safety review of abortion pill will continue into next year (opens Bangor Daily News in a new tab)
Bangor Daily News — is Bangor Daily News biased? Our profile of this outlet
- FDA says its review of abortion pill will continue into next year (opens ABC News in a new tab)
- FDA says it will complete safety review of abortion pill in March (opens NBC News in a new tab)
- FDA says its safety review of abortion pill will continue into next year (opens St Catharines Standard in a new tab)
St Catharines Standard — is St Catharines Standard biased? Our profile of this outlet
- FDA says its safety review of abortion pill will continue into next year (opens The Record in a new tab)
The Record — is The Record biased? Our profile of this outlet
- FDA says its safety review of abortion pill will continue into next year (opens The Hamilton Spectator in a new tab)
The Hamilton Spectator — is The Hamilton Spectator biased? Our profile of this outlet
- FDA says it will complete safety review of abortion pill in March (opens NBC Dallas-Fort Worth in a new tab)
NBC Dallas-Fort Worth — is NBC Dallas-Fort Worth biased? Our profile of this outlet
- FDA says its safety review of abortion pill will continue into next year (opens Durango Herald in a new tab)
Durango Herald — is Durango Herald biased? Our profile of this outlet
- FDA faces court test on abortion pill review (opens Politico in a new tab)
Centre
39- Review could lead to changes (opens Winona Daily News in a new tab)
Winona Daily News — is Winona Daily News biased? Our profile of this outlet
- Review could lead to changes (opens Bristol Herald Courier in a new tab)
Bristol Herald Courier — is Bristol Herald Courier biased? Our profile of this outlet
- FDA expects to draft mifepristone safety review next year; pro-life groups call it 'insufficient' (opens Catholic Review in a new tab)
Catholic Review — is Catholic Review biased? Our profile of this outlet
- FDA Expects To Draft Mifepristone Safety Review Next Year; Pro-Life Groups Call It ‘Insufficient' (opens The Tablet in a new tab)
The Tablet — is The Tablet biased? Our profile of this outlet
- Mifepristone Access by Mail Continues as FDA Tells Louisiana Court Its Safety Review Should Finish by March 2027 (opens Medical Daily in a new tab)
Medical Daily — is Medical Daily biased? Our profile of this outlet
- Health Beat: Mifepristone remains available for at least 2 months as FDA review continues (opens WFMZ in a new tab)
- FDA says its safety review of abortion pill will continue into next year (opens The Record in a new tab)
The Record
- FDA says its safety review of abortion pill will continue into next year (opens ABC Columbia in a new tab)
ABC Columbia — is ABC Columbia biased? Our profile of this outlet
Show 31 more
- FDA says its safety review of abortion pill will continue into next year (opens STAT in a new tab)
- FDA says its safety review of abortion pill will continue into next year (opens Chicago Tribune in a new tab)
Chicago Tribune — is Chicago Tribune biased? Our profile of this outlet
- FDA's abortion pill safety review continuing into next year angers abortion rights opponents (opens CBS News in a new tab)
- FDA's ongoing review of abortion pill frustrates anti-abortion advocates (opens Lex18 NBC in a new tab)
- FDA's ongoing review of abortion pill frustrates anti-abortion advocates (opens WTVR in a new tab)
- FDA says its safety review of abortion pill will continue into next year - Boston News, Weather, Sports (opens WHDH in a new tab)
- FDA Says Its Safety Review of Abortion Pill Will Continue Into Next Year (opens MedPage Today in a new tab)
MedPage Today — is MedPage Today biased? Our profile of this outlet
- FDA's ongoing review of abortion pill frustrates anti-abortion advocates (opens KZTV in a new tab)
- FDA's ongoing review of abortion pill frustrates anti-abortion advocates (opens KJRH in a new tab)
- FDA says its safety review of abortion pill will continue into next year (opens The Columbian in a new tab)
The Columbian — is The Columbian biased? Our profile of this outlet
- FDA's ongoing review of abortion pill frustrates anti-abortion advocates (opens KXLH.com in a new tab)
- FDA's ongoing review of abortion pill frustrates anti-abortion advocates (opens KPAX in a new tab)
- FDA's ongoing review of abortion pill frustrates anti-abortion advocates (opens KTVQ in a new tab)
- FDA's ongoing review of abortion pill frustrates anti-abortion advocates (opens KTVH in a new tab)
- FDA's ongoing review of abortion pill frustrates anti-abortion advocates (opens KBZK in a new tab)
- FDA says its safety review of abortion pill will continue into next year (opens My Mother Lode in a new tab)
My Mother Lode — is My Mother Lode biased? Our profile of this outlet
- FDA says its safety review of abortion pill will continue into next year (opens KHQ Right Now in a new tab)
KHQ Right Now — is KHQ Right Now biased? Our profile of this outlet
- FDA says its safety review of abortion pill will continue into next year (opens KULR-TV in a new tab)
- FDA says its safety review of abortion pill will continue into next year (opens The Northern Virginia Daily in a new tab)
The Northern Virginia Daily — is The Northern Virginia Daily biased? Our profile of this outlet
- FDA says its safety review of abortion pill will continue into next year (opens WV News in a new tab)
- FDA says its safety review of abortion pill will continue into next year (opens Rutland Herald in a new tab)
Rutland Herald — is Rutland Herald biased? Our profile of this outlet
- FDA says its safety review of abortion pill will continue into next year (opens ABC FOX Montana in a new tab)
ABC FOX Montana — is ABC FOX Montana biased? Our profile of this outlet
- FDA says its review of abortion pill will continue into next year (opens Daily News-Record in a new tab)
Daily News-Record — is Daily News-Record biased? Our profile of this outlet
- FDA says its review of abortion pill will continue into next year (opens Bozeman Daily Chronicle in a new tab)
Bozeman Daily Chronicle — is Bozeman Daily Chronicle biased? Our profile of this outlet
- FDA says its review of abortion pill will continue into next year – WTOP News (opens Washington Top News in a new tab)
Washington Top News — is Washington Top News biased? Our profile of this outlet
- FDA says its safety review of abortion pill will continue into next ye (opens WBAL in a new tab)
- FDA says its safety review of abortion pill will continue into next year (opens Newsday in a new tab)
- FDA says its safety review of abortion pill will continue into next year (opens KOB 4 in a new tab)
- FDA says its review of abortion pill will continue into next year (opens WKMG in a new tab)
- FDA: Mifepristone review won’t be done until March (opens The Hill in a new tab)
- FDA says its safety review of abortion pill will continue into next year (opens Winnipeg Free Press in a new tab)
Winnipeg Free Press — is Winnipeg Free Press biased? Our profile of this outlet
Right
18- FDA Delays Review of Abortion Pill, Leaving Women Unprotected (opens Focus on the Family in a new tab)
Focus on the Family — is Focus on the Family biased? Our profile of this outlet
- The FDA’s Broken Promises And The Real Cost Of Mail-Order Abortions (opens The Daily Wire in a new tab)
The Daily Wire — is The Daily Wire biased? Our profile of this outletOpinion
- FDA sets March deadline for abortion pill safety review (opens The Center Square in a new tab)
The Center Square — is The Center Square biased? Our profile of this outlet
- Trump's week in review: FDA update angers pro-lifers; Trump Accounts created for 70M children (opens The Christian Post in a new tab)
The Christian Post — is The Christian Post biased? Our profile of this outlet
- Trump admin says abortion pill review won't be ready until March (opens LifeSiteNews in a new tab)
LifeSiteNews — is LifeSiteNews biased? Our profile of this outlet
- ‘This Is Not Enough’: Pro-Life Groups Blast FDA over Delayed Abortion Pill Review (opens National Review in a new tab)
National Review — is National Review biased? Our profile of this outlet
- Trump Finally Gives Update on Deadly Drug—Why Its Opponents Are Not Happy (opens The Daily Signal in a new tab)
The Daily Signal — is The Daily Signal biased? Our profile of this outlet
- FDA expects to draft mifepristone safety review next year; pro-life groups call it ‘insufficient’ (opens Our Sunday Visitor in a new tab)
Our Sunday Visitor — is Our Sunday Visitor biased? Our profile of this outlet
Show 10 more
- Abortion drug safety review will be completed by March, US FDA says - Regional Media News (opens regionalmedianews.com in a new tab)
regionalmedianews.com — is regionalmedianews.com biased? Our profile of this outlet
- FDA Abortion Pill Review to Continue Into 2027 - The Thinking Conservative News (opens The Thinking Conservative in a new tab)
The Thinking Conservative — is The Thinking Conservative biased? Our profile of this outlet
- FDA Abortion Pill Review to Continue Into 2027 (opens The Epoch Times in a new tab)
The Epoch Times — is The Epoch Times biased? Our profile of this outlet
- Food and Drug Administration expects decision on abortion pill in March (opens Washington Times in a new tab)
Washington Times — is Washington Times biased? Our profile of this outlet
- FDA Says It Won’t Act On Abortion Drugs Till March, 2 Years After Pledging To Review Safety Concerns (opens Conservative Review in a new tab)
Conservative Review — is Conservative Review biased? Our profile of this outlet
- DA Says It Won't Act On Abortion Drugs Till March, 2 Years After Pledging To Review Safety Concerns (opens The Federalist in a new tab)
The Federalist — is The Federalist biased? Our profile of this outlet
- FDA Postpones Review of Dangerous Abortion Pill to March 2027 (opens LifeNews.com in a new tab)
LifeNews.com — is LifeNews.com biased? Our profile of this outlet
- FDA pushes abortion drug safety review back to March (opens World in a new tab)
- FDA Says Its Safety Review of Abortion Pill Will Continue into Next Year (opens The National Herald in a new tab)
The National Herald — is The National Herald biased? Our profile of this outlet
- Statement Ahead of FDA's Oct. 7 Deadline for Mifepristone Study Update (opens SBA Pro-Life America in a new tab)
SBA Pro-Life America — is SBA Pro-Life America biased? Our profile of this outletOpinion
Not rated
12- FDA mifepristone study draws questions from Missouri's Josh Hawley (opens KTTN-FM 92.3 and KGOZ -FM 101.7 Serving north Missouri… in a new tab)
- Study: FDA lacks 'sufficient evidence' of mail-order abortion pill safety (opens ewtnnews.com in a new tab)
ewtnnews.com — is ewtnnews.com biased? Our profile of this outlet
- FDA Continues to Delay Needed Action to Protect Women & Children from Abortion Pill (opens The Iowa Standard in a new tab)
The Iowa Standard — is The Iowa Standard biased? Our profile of this outletOpinion
- Trump admin to give update on abortion drug – why its opponents are not happy (opens The Heartlander in a new tab)
The Heartlander — is The Heartlander biased? Our profile of this outlet
- FDA expects to draft mifepristone safety review next year; pro-life groups call it 'insufficient' (opens The Catholic Sun in a new tab)
The Catholic Sun — is The Catholic Sun biased? Our profile of this outlet
- Anti-abortion advocates fume after FDA declines to immediately impose abortion pill limits (opens BizToc in a new tab)
- Feds unlikely to change abortion pill policy before next year (opens Dailyfly in a new tab)
- FDA Postpones Review of Dangerous Abortion Pill to March 2027 (opens littlebytesnews.com in a new tab)
littlebytesnews.com — is littlebytesnews.com biased? Our profile of this outlet
Show 4 more
- FDA says its safety review of abortion pill will continue into next year (opens Loonie Politics in a new tab)
Loonie Politics — is Loonie Politics biased? Our profile of this outlet
- FDA says its safety review of abortion pill will continue into next year (opens Airdrie City View in a new tab)
Airdrie City View — is Airdrie City View biased? Our profile of this outlet
- FDA says its safety review of abortion pill will continue into next year (opens KXL in a new tab)
- FDA says it will complete safety review of abortion pill in March (opens mnnofa.com in a new tab)
mnnofa.com — is mnnofa.com biased? Our profile of this outlet
How did this read?
About the coverage, not about the story. We do not ask whether you agree with what happened — we have no honest use for that answer.

